|
Phase Ib study: Selective histone deacetylase (HDAC) inhibitor ACY-241 + nivolumab (Nivo) in advanced non-small cell lung cancer (NSCLC). |
|
|
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Merck; Nektar; Novartis; Pfizer; Syndax |
Research Funding - Bristol-Myers Squibb |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
Honoraria - AstraZeneca/MedImmune; CytomX Therapeutics; Merck |
Consulting or Advisory Role - Array BioPharma (Inst) |
Research Funding - Abbvie (Inst); Archer (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst) |